title: Aflibercept.
abstract: In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Stewart
authors.forename: Seden
authors.initials: S
authors.lastname: Grippon
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor